News | October 22, 2025
Cambrex to invest $120 million to expand API manufacturing in US
Expanding US operations to address the increased demand for API development and manufacturing
Expanding US operations to address the increased demand for API development and manufacturing
The collaboration combines the extensive CMC expertise of Sai Life Sciences in API development, Agility Life Sciences in formulation development, and Centrix Pharma Solutions in drug product development and clinical manufacturing
It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals
Newly commissioned MCC in Jhagadia and Dahej and CCS project expansions will unlock an additional 8,800 MTPA, fuelling year-over-year revenue gains of 20%-30% in excipients
Centre for Continuous Manufacturing and Advanced Crystallisation (CMAC) aims to accelerate the digital transformation of CMC development and manufacturing approaches
The company is committed to revolutionizing API development by advancing synthesis and analytical processes that enhance quality and impact lives
Expanded capacity in Nansha, China will support mid-scale manufacturing to ensure a smooth transition between early-phase and large-scale commercial production
The focus of the companies in this partnership is to synergise capabilities, leverage research and bring innovative products in specific therapeutic areas
Steve joins Sai Life Sciences from GlaxoSmithKline (GSK) where he was a department head and member of the global chemical development leadership team.
This rapid analytical technique provides additional information about the polymorph and solid-state properties of active pharmaceutical ingredients (APIs)
Subscribe To Our Newsletter & Stay Updated
